J Jan B van Lanschot
Overview
Explore the profile of J Jan B van Lanschot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
4367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hermus M, van der Wilk B, Chang R, Collee G, Noordman B, Coene P, et al.
Int J Cancer
. 2022 Oct;
152(6):1183-1190.
PMID: 36250325
Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO-study we gained insight in patients'...
12.
Eyck B, Jansen M, Noordman B, Atmodimedjo P, van der Wilk B, Martens J, et al.
J Pathol
. 2022 Oct;
259(1):35-45.
PMID: 36196486
Active surveillance instead of standard surgery after neoadjuvant chemoradiotherapy (nCRT) has been proposed for patients with oesophageal cancer. Circulating tumour DNA (ctDNA) may be used to facilitate selection of patients...
13.
Eyck B, Gao X, Yang Y, van der Wilk B, Wong I, Wijnhoven B, et al.
Br J Surg
. 2022 Aug;
109(12):1312-1318.
PMID: 36036665
Background: Patients with different ethnic and genetic backgrounds may respond differently to anticancer therapies. This study aimed to assess whether patients with oesophageal squamous cell carcinoma (OSCC) treated with neoadjuvant...
14.
van der Zijden C, Eyck B, van der Gaast A, van Doorn L, Nuyttens J, van Lanschot J, et al.
Contemp Clin Trials Commun
. 2022 Jun;
28:100934.
PMID: 35669486
Background: FLOT and CROSS are effective neoadjuvant regimens for esophageal cancer patients. Chemotherapy (FLOT) is aimed to have merely a systemic effect whereas neoadjuvant chemoradiotherapy (CROSS) achieves good locoregional response...
15.
van der Bogt R, van der Wilk B, Oudijk L, Schoon E, van Lijnschoten G, Corporaal S, et al.
Endoscopy
. 2022 Jun;
54(12):1131-1138.
PMID: 35668664
Background: Active surveillance after neoadjuvant treatment is increasingly implemented. The success of this strategy relies on the accurate detection of residual cancer. This study aimed to assess the diagnostic value...
16.
Eyck B, Klevebro F, van der Wilk B, Johar A, Wijnhoven B, van Lanschot J, et al.
Eur J Surg Oncol
. 2021 Nov;
48(3):582-588.
PMID: 34763951
Aim: Compared to open esophagectomy (OE), both totally minimally invasive (TMIE) and laparoscopy-assisted hybrid minimally invasive (HMIE) reduce postoperative morbidity and improve short-term health-related quality of life (HRQoL). We aimed...
17.
van der Wilk B, Spronk I, Noordman B, Eyck B, Haagsma J, Coene P, et al.
Br J Surg
. 2021 Nov;
109(2):169-171.
PMID: 34750625
No abstract available.
18.
Spoor J, Eyck B, Atmodimedjo P, Jansen M, Helmijr J, Martens J, et al.
Ann Transl Med
. 2021 Sep;
9(15):1264.
PMID: 34532401
Circulating tumor DNA (ctDNA) analysis is a promising non-invasive technique for active surveillance after chemoradiotherapy for locally advanced resectable esophageal carcinoma. In other malignancies false-positive results in ctDNA analysis have...
19.
Eyck B, Wijnhoven B, van Lanschot J
J Clin Oncol
. 2021 Aug;
39(28):3190-3191.
PMID: 34339303
No abstract available.
20.
van der Wilk B, Eyck B, Hofstetter W, Ajani J, Piessen G, Castoro C, et al.
Ann Surg
. 2021 Jun;
275(3):467-476.
PMID: 34191461
Objective: To compare overall survival of patients with a cCR undergoing active surveillance versus standard esophagectomy. Summary Of Background Data: One-third of patients with esophageal cancer have a pathologically complete...